Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07790380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

Name: FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. — clinical trial record (NCT07790380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorJiangsu HengRui Medicine Co., Ltd.

Started2026-10-10

View on ClinicalTrials.gov ↗

Jiangsu HengRui Medicine Co., Ltd.

126 trials monitored

See 6 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.

Trial Details

NCT Number	NCT07790380
Lead Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions	Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
Enrollment	480 participants
Start Date	2026-10-10
Primary Completion	2029-06-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-27